Precipio, Inc. — Cyborg Score 4/10

Strategic Profile

Precipio develops precision diagnostic solutions integrating digital morphology, immunophenotyping, and molecular testing to improve diagnosis of leukemia and related blood disorders, designed to enhance accuracy and speed of laboratory workflows. The company offers IV-Cell, a proprietary cell culture media, and HemeScreen, a suite of genetic diagnostic panels.

Cyborg Score Rationale

Precipio shows strong revenue growth trends and institutional investor interest, but faces profitability challenges with negative EPS and EBITDA. Trading significantly below analyst valuations suggests either undervaluation or serious operational concerns that need resolution.

Top Insights

• Revenue growing 27% year-over-year with improving operational metrics, showing market traction
• Trading at significant discount to estimated fair value (77.4% below) despite market volatility
• Recent institutional investor participation indicates growing confidence in platform potential
• Micro-cap scale ($32-42M market cap) presents both liquidity risk and potential upside if diagnostics gain market adoption

Named Competitors

• T2 Biosystems platforms — Rapid molecular diagnostic systems for sepsis and other infectious diseases
• Biodesix diagnostic tests — Protein-based blood tests for cancer and chronic disease management
• ENDRA imaging solutions — Thermal imaging diagnostic technology for tissue characterization

Recent Developments

• (March 2026) Stock trading above 200-day moving average at $24.08 with renewed institutional interest
• (Q3 2025) Multiple hedge funds and institutional investors increased stakes, including AMH Equity raising position 370%
• (Recent) Cardinal Health distribution agreement signed for HemeScreen portfolio expansion

Open the full interactive Precipio, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.